Globally, the reimbursement landscape is constantly evolving. Therapies are generally becoming highly specialized, and more treatments are being developed for rare diseases. The IMAC team have an unparalleled track record for successful reimbursement—read about what IMAC can do for you!

In the landscape of increasing healthcare costs, strategic economic models have become imperative to successful reimbursement strategy in most markets. IMAC has a highly experienced health economic and outcomes research (HEOR) team that have decades of experience developing innovative economic models—read more about IMAC’s modeling services!

Market access in rare disease has unique challenges—limited data, inadequate knowledge base among payers, higher prices, and the lack of dedicated approaches to evaluating rare disease drugs are some of the issues manufacturers face. Read more to see how partnering with the IMAC team who have a deep understanding of market access strategies for rare diseases could help you!

Real-world evidence (RWE) generation continues to be the driver for decision-making by regulators, payers, and providers, and has assumed a progressively greater importance over time to the market access landscape. Read more about how IMAC can help you with RWE.

The Canadian market access landscape has become increasingly more complex. Navigating the best path for your therapy can be challenging. We have extensive expertise in the Canadian landscape—read how IMAC can help!

Private payers are a critical part of the market access landscape in Canada and make up a significant percentage of prescription drug purchases. Find out how IMAC can help you navigate this complex market access path!